First-line treatment for severe aplastic anemia in children: Bone marrow transplantation from a matched family donor versus immunosuppressive therapy

Nao Yoshida, Ryoji Kobayashi, Hiromasa Yabe, Yoshiyuki Kosaka, Hiroshi Yagasaki, Ken Ichiro Watanabe, Kazuko Kudo, Akira Morimoto, Shouichi Ohga, Hideki Muramatsu, Yoshiyuki Takahashi, Koji Kato, Ritsuro Suzuki, Akira Ohara, Seiji Kojima

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The current treatment approach for severe aplastic anemia in children is based on studies performed in the 1980s, and updated evidence is required. We retrospectively compared the outcomes of children with acquired severe aplastic anemia who received immunosuppressive therapy within prospective trials conducted by the Japanese Childhood Aplastic Anemia Study Group or who underwent bone marrow transplantation from an HLA-matched family donor registered in the Japanese Society for Hematopoietic Cell Transplantation Registry. Between 1992 and 2009, 599 children (younger than 17 years) with severe aplastic anemia received a bone marrow transplant from an HLA-matched family donor (n=213) or immunosuppressive therapy (n=386) as first-line treatment. While the overall survival did not differ between patients treated with immunosuppressive therapy or bone marrow transplantation [88% (95% confidence interval: 86-90) versus 92% (90-94)], failure-free survival was significantly inferior in patients receiving immunosuppressive therapy than in those undergoing bone marrow transplantation [56% (54-59) versus 87% (85-90); P<0.0001]. There was no significant improvement in outcomes over the two time periods (1992-1999 versus 2000-2009). In multivariate analysis, age <10 years was identified as a favorable factor for overall survival (P=0.007), and choice of first-line immunosuppressive therapy was the only unfavorable factor for failure-free survival (P<0.0001). These support the current algorithm for treatment decisions, which recommends bone marrow transplantation when an HLA-matched family donor is available in pediatric severe aplastic anemia.

Original languageEnglish
Pages (from-to)1784-1791
Number of pages8
JournalHaematologica
Volume99
Issue number12
DOIs
Publication statusPublished - Dec 1 2014

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'First-line treatment for severe aplastic anemia in children: Bone marrow transplantation from a matched family donor versus immunosuppressive therapy'. Together they form a unique fingerprint.

  • Cite this

    Yoshida, N., Kobayashi, R., Yabe, H., Kosaka, Y., Yagasaki, H., Watanabe, K. I., Kudo, K., Morimoto, A., Ohga, S., Muramatsu, H., Takahashi, Y., Kato, K., Suzuki, R., Ohara, A., & Kojima, S. (2014). First-line treatment for severe aplastic anemia in children: Bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica, 99(12), 1784-1791. https://doi.org/10.3324/haematol.2014.109355